The therapeutic efficacy and safety of the survivin inhibitor YM155 has been evaluated in phase I and II clinical trials in different types of cancers (Giaccone et al., 2009; Miura et al., 2011) and in on-going trials registered in clinicaltrials.gov. This evidence concerns the gene BIRC5 and cancer.